N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors

1. A method of treating chronic lymphocytic leukemia (CLL), by inhibiting cyclin dependent kinase in a patient comprising administering a therapeutically effective amount of at least one compound represented by the structural formula:

wherein:

R is heteroaryl, wherein said heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 6 , —C(R 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O) 2 R 7 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

R 2 is selected from the group consisting of R 9 , alkyl, alkynyl, aryl, heteroaryl, CF 3 , alkynylalkyl, cycloalkyl, —C(O)OR 4 , alkyl substituted with 1-6 substitutents independently selected from the group R 9 ,

 wherein the aryl in the above-noted definitions for R 2 can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, CN, —OR 5 , SR 5 , —CH 2 OR 5 , —C(O)R 5 , —SO 3 H, —S(O) 2 R 6 , —S(O) 2 NR 5 R 6 , —NR 5 R 6 , —C(O)NR 5 R 6 , —CF 3 , and —OCF 3 ;

R 3 is selected from the group consisting of H, halogen, —NR 5 R 6 , —C(O)OR 4 , —C(O)NR 5 R 6 , alkyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl,

wherein each of said alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl for R 3 and the heterocyclyl moieties whose structures are shown immediately above for R 3 can be substituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , CN, —OCF 3 , —(CR 4 R 5 ) n OR 5 , —OR 5 , —NR 5 R 6 , —(CR 4 R 5 ) n NR 5 R 6 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

R 4 is H, halo or alkyl;

R 5 is H or alkyl;

R 6 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 10 , —N(R 5 )(tertiary Butoxycarbonyl), —(CR 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 10 , —SO 3 H, —SR 10 , —S(O) 2 R 7 , —S(O) 2 NR 5 R 10 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 10 ;

R 10 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 4 R 5 , —N(R 5 )(tertiaryButoxycarbonyl), —(CR 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)NR 4 R 5 , —C(O)R 5 , —SO 3 H, —SR 5 , —S(O) 2 R 7 , —S(O) 2 NR 4 R 5 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 4 R 5 ;

or optionally (i) R 5 and R 10 in the moiety —NR 5 R 10 , or (ii) R 5 and R 6 in the moiety —NR 5 R 6 , may be joined together to form a heterocyclyl moiety, with each of said heterocyclyl moiety being unsubstituted or optionally independently being substituted with one or more R 9 groups;

R 7 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, cycloalkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl for R 7 can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 10 , —CH 2 OR 5 , —C(O) 2 R 5 , —C(O)NR 5 R 10 , —C(O)R 5 , —SR 10 , —S(O) 2 R 10 , —S(O) 2 NR 5 R 10 , —N(R 5 )S(O) 2 R 10 , —N(R 5 )C(O)R 10 and —N(R 5 )C(O)NR 5 R 10 ;

R 8 is selected from the group consisting of R 6 , —C(O)NR 5 R 10 , —CH 2 OR 4 , —C(O)OR 6 , —C(O)R 7 and —S(O) 2 R 7 ;

R 9 is selected from the group consisting of halogen, —CN, —NR 5 R 6 , —(CH 2 ) n OR 4 , —C(O) 2 R 6 , —C(O)NR 5 R 6 , —OR 6 , —SR 6 , —S(O) 2 )R 7 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

m is 0 to 4; and

n is 1 to 4, or a pharmaceutically acceptable salt thereof, to said patient, wherein said cyclin dependent kinase is CDK1 or CDK2.

2. The method of claim 1 , wherein said cyclin dependent kinase is CDK2.

3. The method of claim 1 further comprising administering an amount of at least one second compound, said second compound being selected from the group consisting of cisplatin, doxorubicin, irinotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-flourouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine-11-yl]-1piperidinyl]-2oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyt protein transferase inhibitor), BMS 214662 (a famesyl protein transferase inhibitor), gefitinib, erlotinib hydrochloride, imatinib, interferon alpha-2b (recombinant), ara-C, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, sreptozocin, dacarbazine, floxuridine, 6-mercaptopurine, 6-thiogaunine, fludarabine phosphate, leucovirin, oxaliplatin, pentostatin, vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, mitomycin-C, L-asparaginase, teniposide, 17-alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, fluoxymesterone, dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydoroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, vinorelbine, anastrazole, letrazole, capecitabine, raloxifene, or Hexamethylmelamine

wherein the amounts of the first compound and said second compound result in a desired therapeutic effect.

4. The method of claim 3 , further comprising radiation therapy.

5. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound represented by the structural formula:

wherein:

R is heteroaryl, wherein said heteroaryl can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 6 , —C(R 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O) 2 R 7 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

R 2 is selected from the group consisting of R 9 , alkyl, alkynyl, aryl, heteroaryl, CF 3 , alkynylalkyl, cycloalkyl, —C(O)OR 4 , alkyl substituted with 1-6 substitutents independently selected from the group R 9 ,

 wherein the aryl in the above-noted definitions for R 2 can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, CN, —OR 5 , SR 5 , —CH 2 OR 5 , —C(O)R 5 , —SO 3 H, —S(O) 2 R 6 , —S(O) 2 NR 5 R 6 , —NR 5 R 6 , —C(O)NR 5 R 6 , —CF 3 , and —OCF 3 ;

R 3 is selected from the group consisting of H, halogen, —NR 5 R 6 , —C(O)OR 4 , —C(O)NR 5 R 6 , alkyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl,

 wherein each of said alkyl, cycloalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl for R 3 and the heterocyclyl moieties whose structures are shown immediately above for R 3 can be substituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , CN, —OCF 3 , —(CR 4 R 5 ) n OR 5 , —OR 5 , —NR 5 R 6 , —(CR 4 R 5 ) n NR 5 R 6 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 6 , —SR 6 , —S(O) 2 R 6 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

R 4 is H, halo or alkyl;

R 5 is H or alkyl;

R 6 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 10 , —N(R 5 )(tertiary Butoxycarbonyl), —(CR 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)R 5 , —C(O)NR 5 R 10 , —SO 3 H, —SR 10 , —S(O) 2 R 7 , —S(O) 2 NR 5 R 10 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 10 ;

R 10 is selected from the group consisting of H, alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl, wherein each of said alkyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, and heteroarylalkyl can be unsubstituted or optionally substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 4 R 5 , —N(R 5 )(tertiaryButoxycarbonyl), —(CR 4 R 5 ) n OR 5 , —C(O) 2 R 5 , —C(O)NR 4 R 5 , —C(O)R 5 , —SO 3 H, —SR 5 , —S(O) 2 R 7 , —S(O) 2 NR 4 R 5 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 4 R 5 ;

or optionally (i) R 5 and R 10 in the moiety —NR 5 R 10 , or (ii) R 5 and R 6 in the moiety —NR 5 R 6 , may be joined together to form a heterocyclyl moiety, with each of said heterocyclyl moiety being unsubstituted or optionally independently being substituted with one or more R 9 groups;

R 7 is selected from the group consisting of alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl and heteroarylalkyl, wherein each of said alkyl, cycloalkyl, heteroarylalkyl, aryl, heteroaryl and arylalkyl for R 7 can be unsubstituted or optionally independently substituted with one or more moieties which can be the same or different, each moiety being independently selected from the group consisting of halogen, alkyl, aryl, cycloalkyl, CF 3 , OCF 3 , CN, —OR 5 , —NR 5 R 10 , —CH 2 OR 5 , —C(O) 2 R 5 , —C(O)NR 5 R 10 , —C(O)R 5 , —SR 10 , —S(O) 2 R 10 , —S(O) 2 NR 5 R 10 , —N(R 5 )S(O) 2 R 10 , —N(R 5 )C(O)R 10 and —N(R 5 )C(O)NR 5 R 10 ;

R 8 is selected from the group consisting of R 6 , —C(O)NR 5 R 10 , —CH 2 OR 4 , —C(O)OR 6 , —C(O)R 7 and —S(O) 2 R 7 ;

R 9 is selected from the group consisting of halogen, —CN, —NR 5 R 6 , —(CH 2 ) n OR 4 , —C(O) 2 R 6 , —C(O)NR 5 R 6 , —OR 6 , —SR 6 , —S(O) 2 R 7 , —S(O) 2 NR 5 R 6 , —N(R 5 )S(O) 2 R 7 , —N(R 5 )C(O)R 7 and —N(R 5 )C(O)NR 5 R 6 ;

m is 0 to 4; and

n is 1 to 4, or a pharmaceutically acceptable salt thereof in combination with at least one pharmaceutically acceptable carrier.

6. The pharmaceutical composition of claim 5 , additionally comprising one or more additional compounds selected from the group consisting of cisplatin, doxorubicin, etoposide, irinotecan, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-flourouracil, methoxtrexate, temozolomide, cyclophosphamide, 4-[2-[4-[(11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine-11-yl]-1-piperidinyl]-2-oxoethyl]-1-piperidinecarboxamide, tipifarnib, L778,123 (a farnesyt protein transferase inhibitor), BMS 214662 ( a famesyl protein transferase inhibitor), gefitinib, erlotinib hydrochloride, imatinib, interferon alpha-2b (recombinant), ara-C, gemcitabine, uracil mustard, chlormethine, ifosfamide, melphalan, chlorambucil, pipobroman, triethylenemelamine, triethylenethiophosphoramine, busulfan, carmustine, lomustine, streptozocin, dacarbazine, floxuridine, 6-mercaptopurine, 6-thiogaunine, fludarabine phosphate, leucovirin, oxaliplatin, pentostatin, vinblastine, vincristine, vindesine, dactinomycin, daunorubicin, epirubicin, idarubicin, mithramycin, mitomycin-C, L-asparaginase, teniposide, 17-alpha-ethinylestradiol, diethylstilbestrol, testosterone, prednisone, flouxymesterone, dromostanolone propionate, testolactone, megestrolacetate, methylprednisolone, methyltestosterone, prednisolone, triamcinolone, chlorotrianisene, hydoroxyprogesterone, aminoglutethimide, estramustine, medroxyprogesteroneacetate, leuprolide, flutamide, toremifene, goserelin, carboplatin, hydroxyurea, amsacrine, procarbazine, mitotane, mitoxantrone, levamisole, vinorelbine, anastrazole, letrazole, capecitabine, raloxifene, or Hexamethylmelamine.

7. the pharmaceutical composition of claim 6 wherein said additional compound is temozolomide.

8. The pharmaceutical composition of claim 5 , wherein the pharmaceutical composition is administered together, concurrently or sequentially, with temozolommide.

9. The pharmaceutical composition of claim 5 , wherein said pharmaceutical composition is administered together, concurrently or sequentially, with radiation therapy.

10. The pharmaceutical composition of claim 6 , wherein at least one of the additional compounds are administered together, concurrently or sequentially, with radiation therapy.

11. A method of treating chronic lymphocytic leukemia (CLL), comprising administering the pharmaceutical composition of claim 5 to a patient in need thereof.

12. A method of treating chronic lymphocytic leukemia (CLL), comprising administering the pharmaceutical composition of claim 6 to a patient in need thereof chronic lymphocytic leukemia (CLL).